pISSN 2636-0004eISSN 2636-0012
pISSN 2636-0004Detailed Characteristics of Patients with Prior Systemic Chemotherapy
| Patient | RFA/MWA | K-ras oncogene(wild/mutant) | Positivity for any liver lesion 30–50 mm in diameter |
Lung metastasis | Colorectal origin (right/left-sided) | Systemic chemotherapy |
|---|---|---|---|---|---|---|
| #1 | MWA | Mutant | Negative | 2 | Left | FOLFOX + Bevacizumab |
| #2 | MWA | Mutant | Negative | 1 | Left | FOLFOX + Bevacizumab |
| #3 | MWA | Mutant | Negative | 0 | Left | FOLFIRI + Bevacizumab |
| #4 | MWA | Wild | Negative | 0 | Left | FOLFOX + Cetuximab |
| #5 | MWA | Mutant | Negative | 0 | Left | FOLFOX + Bevacizumab |
| #6 | MWA | Mutant | Positive | 3 | Right | FOLFIRI + Bevacizumab |
| #7 | MWA | Mutant | Positive | 4 | Left | FOLFOX + Bevacizumab |
| #8 | MWA | Mutant | Positive | 0 | Left | FOLFOX + Bevacizumab |
| #9 | MWA | Wild | Negative | 0 | Left | FOLFOX + Cetuximab |
| #10 | MWA | Wild | Positive | 0 | Left | FOLFOX + Panitumumab |
| #11 | MWA | Mutant | Negative | 0 | Left | FOLFOX + Bevacizumab |
| #12 | MWA | Wild | Positive | 1 | Left | FOLFOX + Panitumumab |
| #13 | MWA | Wild | Positive | 1 | Left | FOLFOX + Cetuximab |
| #14 | MWA | Mutant | Positive | 5 | Left | FOLFIRI + Bevacizumab |
| #15 | MWA | Wild | Negative | 3 | Left | FOLFOX + Panitumumab |
| #16 | RFA | Wild | Negative | 0 | Left | FOLFOX + Cetuximab |
| #17 | RFA | Wild | Positive | 0 | Left | FOLFOX + Cetuximab |
| #18 | RFA | Wild | Negative | 0 | Left | FOLFOX + Cetuximab |
| #19 | RFA | Wild | Negative | 0 | Right | FOLFOX + Cetuximab |
| #20 | RFA | Wild | Negative | 0 | Right | FOLFOX + Panitumumab |
| #21 | RFA | Mutant | Negative | 3 | Left | FOLFOX + Bevacizumab |
| #22 | RFA | Wild | Negative | 0 | Left | FOLFOX + Cetuximab |
| #23 | RFA | Wild | Negative | 0 | Left | FOLFIRI + Panitumumab |
| #24 | RFA | Mutant | Negative | 0 | Left | FOLFOX + Bevacizumab |
| #25 | RFA | Mutant | Negative | 1 | Left | FOLFOX + Bevacizumab |
RFA, radiofrequency ablation; MWA, microwave ablation; FOLFOX, folinic acid, fluorouracil, and oxaplatin; FOLFIRI, folinic acid, fluorouracil, and irinotecan.
*The patients with liver metastases larger than 30 mm in diameter after systemic chemotherapy.
†The pre-procedural systemic chemotherapy choice was neoadjuvant in all patients. In addition, all patients were partially responsive to prior chemotherapy.